Azitra Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
67.1%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.26next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly10.1MTarget: Sufficient capital to fund operations beyond 12 months
ATR-12 Phase 1b Trial Enrollment Quarterly50.0Target: 100% enrollment and completion
ATR-04 Phase 1/2 Trial Cohort 1 Dosing QuarterlyTarget: Complete cohort 1 dosing and evaluate safety
Watch Items
- ATR-12 Phase 1b Topline Data ReadoutTrigger: H2 2026Action: Review safety, tolerability, and LEKTI protein expression levels to determine Phase 2 trial design.
- ATR-04 Phase 1/2 Cohort 1 Topline Data ReadoutTrigger: H2 2026Action: Analyze safety and efficacy in oncology patients experiencing EGFRi-associated rash.
- ATR-COSF Cosmetic Application StudyTrigger: Q3 2026Action: Initiate human cosmetic application study to evaluate recombinant filaggrin protein for fine lines and wrinkles.
Research as of 20 Jun 2026